首页 / 院系成果 / 成果详情页

Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation. 期刊论文

编号：

1D7E6A213BBA4BFE7C06A2C58A97B2EB
作者：

Wang Ruiqi^[1];Cai Jing^[2];Chen Ziqi^[3];Tian Hao^[3];Cong Dan^[3];Bai Yuansong(白元松)^[3]Zhang Wenlong(张文龙)^[4]
地址：

[1]Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.;Department of Hematology and Oncology, First Hospital of Jilin University, Changchun, 130000, China.
[2]Department of Pediatrics, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
[3]Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
[4]Department of Hematology and Oncology, China-Japan Union Hospital of Jilin University, Changchun, 130033, China. wenxu@jlu.edu.cn.
语种：

英文
期刊：

Scientific reports ISSN：2045-2322 2025 年 15 卷 1 期 (5393 - ) ; 2025-Feb-13
收录：
关键词：

Autologous hematopoietic stem cell transplantation Hematopoietic reconstitution Newly diagnosed multiple myeloma Recombinant human thrombopoietin
摘要：

To evaluate the effect of recombinant human thrombopoietin (rhTPO) on platelet engraftment after autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM) patients. Clinical data of 40 NDMM patients who underwent high-dose melphalan conditioning and ASCT were analyzed, with 26 receiving rhTPO and 14 in the control group. The primary study endpoint was the median time to platelet engraftment. The secondary study endpoints included the median time to neutrophil engraftment, number of blood cells transfused, treatment-related adverse events, long-term hematopoietic reconstitution, and economic cost-effectiveness. The median time to neutrophil engraftment was 10.92 and 11.14 days in the rhTPO and control groups, respectively (p = 0.405). The median time to platelet engraftment (11.5 vs. 11.36 days, p = 0.776), median number of erythrocyte infusions (0.23 vs. 0 units, p = 0.326), and median number of platelet infusions (1.615 vs. 1.5 units, p = 0.721) did not significantly differ between the groups. The median hospitalization duration was 27.08 and 25.07 days in the rhTPO and control groups, respectively (p = 0.193). The median hospitalization cost was RMB 73,846 and RMB 54,136 in the rhTPO and control groups, respectively (p < 0.001). At 180 days post-transplantation, the neutrophil count, hemoglobin level, and platelet count did not significantly differ between the groups. Administering rhTPO after ASCT for NDMM did not accelerate platelet engraftment or reduce platelet transfusions, but increased hospitalization costs.;
推荐引用方式
GB/T 7714：

Wang Ruiqi,Cai Jing,Chen Ziqi, et al. Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation. [J].Scientific reports,2025,15(1):5393-.
APA：

Wang Ruiqi,Cai Jing,Chen Ziqi,Tian Hao,&Zhang Wenlong.(2025).Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation. .Scientific reports,15(1):5393-.
MLA：

Wang Ruiqi, et al. "Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation." .Scientific reports 15,1(2025):5393-.
入库时间：

3/13/2025 9:18:00 PM
更新时间：

3/13/2025 9:18:00 PM

浏览次数：1  下载次数：0

分享到：

浏览次数：1

下载次数：0

打印次数：0